FDA Maps Pathways To Compliance At Unapproved Drugs Workshop
This article was originally published in The Tan Sheet
Executive Summary
FDA plans to increase enforcement actions against marketed unapproved drugs in the coming year, but hopes to cooperate with firms willing to come to the table seeking approval for currently unapproved products